SCHEMBL4724769

SCHEMBL4724769

CCCOc1c[nH][c]c1-c1cccc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.43
CNR2 P34972 2/20 0.43
HTR1B P28222 10/20 0.43
HTR1D P28221 3/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
SLC6A4 P31645 1/20 0.38
HRH1 P35367 1/20 0.38
PLA2G1B P04054 1/20 0.37
HSP90AA1 P07900 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA7 P36544 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722874 0.93 HTR1B (0.45) CNR1CNR2HTR1BHTR1DSLC6A4
SCHEMBL4722698 0.89 ENPP1 (0.43) HTR1BHTR1DTSHRCHRNB4CHRNA3
SCHEMBL4723193 0.81 MAPT (0.42) CNR2MEN1KMT2AL3MBTL1
SCHEMBL4720942 0.77 HTR1B (0.41) CNR1CNR2HTR1BHTR1DSLC6A4
SCHEMBL4722616 0.77 ADRB2 (0.39) MEN1KMT2ATSHRSLC6A4L3MBTL1
SCHEMBL4722971 0.77 CNR1 (0.44) CNR1CNR2HTR1BHTR1DMEN1
SCHEMBL28075369 0.76 HTR1B (0.54) CNR1CNR2HTR1BHTR1DSLC6A4
SCHEMBL4724637 0.75 HTR1B (0.43) CNR1CNR2HTR1BHTR1DMEN1
SCHEMBL4719990 0.74 CNR1 (0.41) CNR1CNR2HTR1BHTR1DMEN1
SCHEMBL2116954 0.72 HTR1B (0.70) CNR1CNR2HTR1BHTR1DSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CNR1 318/4885CNR2 385/4885HTR1B 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.